Genomic and molecular profiling predicts response to temozolomide in melanoma.

@article{Augustine2009GenomicAM,
  title={Genomic and molecular profiling predicts response to temozolomide in melanoma.},
  author={Christina K. Augustine and Jin Soo Yoo and Anil Potti and Yasunori Yoshimoto and Patricia A. Zipfel and Henry S. Friedman and J. R. Nevins and Francis R Ali-Osman and Douglas S. Tyler},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2009},
  volume={15 2},
  pages={502-10}
}
PURPOSE Despite objective response rates of only approximately 13%, temozolomide remains one of the most effective single chemotherapy agents against metastatic melanoma, second only to dacarbazine, the current standard of care for systemic treatment of melanoma. The goal of this study was to identify molecular and/or genetic markers that correlate with, and could be used to predict, response to temozolomide-based treatment regimens and that reflect the intrinsic properties of a patient's tumor… CONTINUE READING